ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/003/SRR26901303/SRR26901303_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/097/SRR26901297/SRR26901297_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/007/SRR26901307/SRR26901307_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/005/SRR26901305/SRR26901305_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/095/SRR26901295/SRR26901295_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/000/SRR26901300/SRR26901300_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/009/SRR26901309/SRR26901309_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/008/SRR26901308/SRR26901308_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/011/SRR26901311/SRR26901311_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/012/SRR26901312/SRR26901312_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/098/SRR26901298/SRR26901298_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/012/SRR26901312/SRR26901312_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/096/SRR26901296/SRR26901296_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/006/SRR26901306/SRR26901306_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/000/SRR26901300/SRR26901300_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/004/SRR26901304/SRR26901304_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/010/SRR26901310/SRR26901310_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/097/SRR26901297/SRR26901297_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/013/SRR26901313/SRR26901313_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/007/SRR26901307/SRR26901307_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/001/SRR26901301/SRR26901301_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/005/SRR26901305/SRR26901305_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/099/SRR26901299/SRR26901299_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/013/SRR26901313/SRR26901313_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/009/SRR26901309/SRR26901309_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/095/SRR26901295/SRR26901295_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/002/SRR26901302/SRR26901302_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/001/SRR26901301/SRR26901301_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/003/SRR26901303/SRR26901303_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/006/SRR26901306/SRR26901306_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/098/SRR26901298/SRR26901298_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/014/SRR26901314/SRR26901314_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/010/SRR26901310/SRR26901310_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/002/SRR26901302/SRR26901302_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/008/SRR26901308/SRR26901308_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/004/SRR26901304/SRR26901304_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/011/SRR26901311/SRR26901311_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/014/SRR26901314/SRR26901314_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/099/SRR26901299/SRR26901299_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR269/096/SRR26901296/SRR26901296_1.fastq.gzprimaryOK200GenomicsMolecular Cardiology, Department of Medicine I, Klinikum rechts der Isar – Technical University Munichhttps://www.ebi.ac.uk/ena/browser/view/PRJNA1043634Homo sapiensxref:PubMed:39661983A novel strategy to hinder the progression of multiple myeloma involves inhibiting NAD+ production. While solely targeting the NAMPT enzyme proved ineffective, the Preiss-Handler pathway, especially NAPRT1, emerged as pivotal in rescuing cancer cells. Cells lacking NAPRT1 become more susceptible to oxidative stress, and the dual targeting of NAMPT/NAPRT1 increased the efficacy of chemotherapy in multiple myelom. Overall design: RNA samples extracted from tumoural CD138-positive plasmacells purified from 20 local NDMM patients were profiled for correlation analysis with clinical dataENAfalseNAD+ metabolism restriction boosts high-dose melphanan efficacy in multiple myeloma patientsNAD+ metabolism restriction boosts high-dose melphanan efficacy in multiple myeloma patients2025-09-242024-12-26PRJNA1043634GSE248379960639661983